<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071772</url>
  </required_header>
  <id_info>
    <org_study_id>M20080151</org_study_id>
    <nct_id>NCT01071772</nct_id>
  </id_info>
  <brief_title>The Effect of Hyperglycemia on LV Function and Exercise Capacity in Diabetics With and Without Heart Failure.</brief_title>
  <acronym>METAMOD</acronym>
  <official_title>Metabolic Substrate Modulation in Insulin Treated Diabetics With and Without Heart Failure: The Effect of Hyperglycemia on Left Ventricular Function and Exercise Capacity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region midtjyllands sundhedsvidenskabelige forskningsfond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes and Heart Failure are diseases with high morbidity and increased risk of death.
      Former investigations has shown that diabetes worsens the prognosis of heart failure. However
      it is uncertain how short term diabetic dysregulation in type 2 diabetics affect cardiac
      function.

      Our hypothesis is that short term dysregulation affects left ventricular function and
      exercise capacity in insulin treated type 2 diabetics with and without heart failure.

      To elucidate this hypothesis diabetic patients with and without heart failure will be
      investigated after overnight state of either high or normal blood glucose levels on two
      separate occasions. Metabolic and hormonal parameters will be measured. Systolic and
      diastolic cardiac function will be assessed, exercise capacity and post exercise regional
      myocardial tissue velocity as well as 6 minutes walk test will be investigated on both
      occasions. The study will be a randomized cross-over design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1: Cardiac systolic (EF by 2D and 3D echocardiography) and diastolic (eÂ´/E and E/A) function before and after exercise.</measure>
    <time_frame>1-4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>1-4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional left ventricular function before and after maximum exercise(regional 2D tissue velocity and strain)</measure>
    <time_frame>1-4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Heart Failure</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>euglycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>hyperglycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin</intervention_name>
    <description>There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.</description>
    <arm_group_label>euglycemia</arm_group_label>
    <arm_group_label>hyperglycemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Either normal ejection fraction (EF) or heart failure (EF =&lt;45%)

          -  Insulin treated type 2

        Exclusion Criteria:

          -  Forme stroke with significant physically or mentally disabilitating disorders

          -  advanced renal disease (creatinine levels &gt;220 mM)

          -  advanced lever disease (alanine aminotransferase &gt; 3 times over reference level).

          -  pregnancy

          -  other significant disabilitating disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Erik Boedker, Prof, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of cardiolgy, Aarhus University hospital, Skejby. Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department ofCardiology, Aarhus University Hospital, Skejby</name>
      <address>
        <city>Aarhus</city>
        <state>Region Midtjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Roni Ranghoej Nielsen</name_title>
    <organization>Dept. of cardiology, Aarhus University hospital, Skejby, Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

